Akums Drugs & Pharmaceuticals to Hold Board Meeting on May 14, 2026 for FY26 Financial Results and Dividend Consideration

Akums Drugs & Pharmaceuticals has notified the stock exchanges of an upcoming board meeting scheduled for Thursday, May 14, 2026. The intimation was filed pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was communicated to both the National Stock Exchange of India Ltd. and BSE Limited on May 11, 2026.

Board Meeting Details

The following key agenda items are scheduled for consideration at the board meeting:

Parameter:	Details
Meeting Date:	Thursday, May 14, 2026
Financial Results:	Audited Standalone & Consolidated
Period Under Review:	Quarter and financial year ended March 31, 2026
Dividend Consideration:	Recommendation of dividend, if any, for FY 2025-26
Regulatory Reference:	Regulation 29, SEBI (LODR) Regulations, 2015

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of Akums Drugs and Pharmaceuticals is currently closed. The trading window will reopen 48 hours after the declaration of the financial results at the aforementioned board meeting.

The intimation was signed by Dharamvir Malik, Company Secretary & Compliance Officer of Akums Drugs and Pharmaceuticals Limited, on May 11, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.92%	-5.50%	+2.41%	+20.47%	+4.22%	-33.64%

Akums Drugs & Pharma has disclosed that it received an ESG rating of 63 for the Financial Year 2024-25, as intimated to the stock exchanges on 8th May, 2026. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026.

ESG Rating Details

The rating was assigned by NSE Sustainability Ratings & Analytics Limited (NSE Sustainability), a subsidiary of NSE Indices Limited and a registered ESG Rating Provider. The company has clarified that it did not engage NSE Sustainability for this rating, and the assessment was voluntarily conducted based on publicly available information.

Key details of the ESG rating disclosure are summarised below:

Parameter:	Details
ESG Rating:	63
Financial Year:	2024-25
Rating Date:	7th May, 2026
Rating Agency:	NSE Sustainability Ratings & Analytics Limited
Agency Type:	Registered ESG Rating Provider
Basis of Rating:	Publicly available information
Company Engagement:	Not engaged by the company

Regulatory Disclosure

The intimation was filed by Dharamvir Malik, Company Secretary & Compliance Officer of Akums Drugs and Pharmaceuticals Limited, on 8th May, 2026. The disclosure was addressed to the Listing Departments of both the National Stock Exchange of India Ltd. and BSE Limited, in compliance with applicable SEBI regulations. The full ESG rating is accessible on the NSE Sustainability platform at the link provided in the official communication.